CollPlant Biotechnologies Ltd. (CLGN)
NASDAQ: CLGN · Real-Time Price · USD
2.880
+0.110 (3.97%)
Aug 7, 2025, 4:00 PM - Market closed
CollPlant Biotechnologies Revenue
CollPlant Biotechnologies had revenue of $2.06M in the quarter ending March 31, 2025, with 1,996.94% growth. This brings the company's revenue in the last twelve months to $2.47M, down -76.73% year-over-year. In the year 2024, CollPlant Biotechnologies had annual revenue of $515.00K, down -95.30%.
Revenue (ttm)
$2.47M
Revenue Growth
-76.73%
P/S Ratio
13.35
Revenue / Employee
$43,368
Employees
57
Market Cap
36.62M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 515.00K | -10.44M | -95.30% |
Dec 31, 2023 | 10.96M | 10.66M | 3,565.22% |
Dec 31, 2022 | 299.00K | -15.34M | -98.09% |
Dec 31, 2021 | 15.64M | 9.50M | 154.86% |
Dec 31, 2020 | 6.14M | 3.82M | 164.75% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CLGN News
- 3 days ago - COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS - PRNewsWire
- 25 days ago - CollPlant Appoints Collagen Biomaterials Expert as New Head of North America Commercial Operations - PRNewsWire
- 2 months ago - COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIES - PRNewsWire
- 2 months ago - COLLPLANT BIOTECHNOLOGIES ANNOUNCES EUROPEAN PATENT ALLOWANCE SECURED FOR ITS COLLAGEN-BASED FORMULATIONS USABLE AS SOFT TISSUE FILLERS AND IMPLANTS - PRNewsWire
- 2 months ago - COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES - PRNewsWire
- 2 months ago - COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE - PRNewsWire
- 3 months ago - COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS - PRNewsWire
- 4 months ago - CollPlant's Collink.3D® BioInks and Technologies Offer a Relevant and Timely Solution to FDA's Plan to Reduce Animal Testing in Preclinical Safety Studies - PRNewsWire